Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
RemeGen Co. Ltd. Class H ( (HK:9995) ) just unveiled an announcement.
RemeGen Co., Ltd. has announced that its board of directors will convene on October 30, 2025, to review and approve the company’s unaudited third-quarter results for the period ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market position and stakeholder interests.
The most recent analyst rating on (HK:9995) stock is a Sell with a HK$89.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company based in the People’s Republic of China, operating in the biotechnology industry. The company focuses on the development and commercialization of innovative biologic drugs, aiming to address unmet medical needs in various therapeutic areas.
Average Trading Volume: 7,909,183
Technical Sentiment Signal: Buy
Current Market Cap: HK$57.87B
See more insights into 9995 stock on TipRanks’ Stock Analysis page.